Treatment of renal carcinoma using antibodies against the EGFr
Details for Australian Patent Application No. 2003239505 (hide)
Event Publications
11 September 2003 Complete Application Filed
Priority application(s): 60/382,152 20.05.02 US
5 February 2004 Application Open to Public Inspection
Published as AU-A-2003239505
2 August 2007 Change of Name(s) of Applicant(s), Section 104
Immunex Corporation; Abgenix, Inc. The name of the applicant has been changed to Immunex Corporation; Amegen Fremont Inc. 2004
30 August 2007 Corrigenda
Change of Names(s) of Applicant(s), Section 104 - 2003 Under the name Amegen Fremont Inc. and Immunex Corporation, application No. 2003239505, under INID(71), correct the name to read Amgen Fremont Inc. and Immunex Corporation
17 December 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired
This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
2003239506-Automatic point source biological agent detection system
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional
![](/images/main/3dbox_small.png)
- Editable Word format reports
- For IP Professionals
- Multiuser